nach oben

Supportive Care in Cancer

Erschienen in:

21.08.2020 | Commentary

Immunotherapy-mediated dermatological adverse events: the urgent need for a common, clinically meaningful, management strategy

verfasst von: Zoe Apalla, Vincent Sibaud

Erschienen in: Supportive Care in Cancer | Ausgabe 12/2020

Einloggen, um Zugang zu erhalten

Excerpt

The introduction of immune checkpoint inhibitors as a treatment modality in advanced malignancies has revolutionized the field of oncology therapeutics. Immunotherapy-mediated adverse events (irAEs) represent a major drawback of their use. Dermatologic AE are among the most common irAEs, reported in about one-third of all treated patients [1]. …

Nur mit Berechtigung zugänglich

Sibaud V (2018) Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy. Am J Clin Dermatol 19:345–361CrossRef

Apalla Z, Lallas A, Delli F, Lazaridou E et al (2020) Management of immune checkpoint inhibitor-induced bullous pemphigoid. J Am Acad Dermatol 16:S0190-9622 (20)30910-5. https://doi.org/10.1016/j.jaad.2020.05.045CrossRef

Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner JM, Ginex P, Hallmeyer S, Holter Chakrabarty J, Leighl NB, Mammen JS, McDermott DF, Naing A, Nastoupil LJ, Phillips T, Porter LD, Puzanov I, Reichner CA, Santomasso BD, Seigel C, Spira A, Suarez-Almazor ME, Wang Y, Weber JS, Wolchok JD, Thompson JA, in collaboration with the National Comprehensive Cancer Network (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 36:1714–1768CrossRef

Phillips GS, Wu J, Hellmann MD, Postow MA, Rizvi NA, Freites-Martinez A, Chan D, Dusza S, Motzer RJ, Rosenberg JE, Callahan MK, Chapman PB, Geskin L, Lopez AT, Reed VA, Fabbrocini G, Annunziata MC, Kukoyi O, Pabani A, Yang CH, Chung WH, Markova A, Lacouture ME (2019) Treatment outcomes of immune-related cutaneous adverse events. J Clin Oncol 37:2746–2758CrossRef

Tattersall IW, Leventhal JS (2020) Cutaneous toxicities of immune checkpoint inhibitors: the role of the dermatologist. Yale J Biol Med 93:123–132PubMedPubMedCentral

Bhor U, Pande S (2006) Scoring systems in dermatology. J Dermatol Venereol Leprol 72:315–321CrossRef

Amatore F, Villani A-P, Tauber M, Viguier M, Guillot B, the Psoriasis Research Group of the French Society of Dermatology (Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie) (2019) French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults. J Eur Acad Dermatol Venereol 33:464–483CrossRef

U.S Department of Health and Human Services (November 27, 2017) https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf 2. Accessed 20 June 2020

Titel: Immunotherapy-mediated dermatological adverse events: the urgent need for a common, clinically meaningful, management strategy
verfasst von: Zoe Apalla
Vincent Sibaud
Publikationsdatum: 21.08.2020
Verlag: Springer Berlin Heidelberg
Erschienen in: Supportive Care in Cancer / Ausgabe 12/2020
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-020-05701-9

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Immunotherapy-mediated dermatological adverse events: the urgent need for a common, clinically meaningful, management strategy

Excerpt

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2020

Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune checkpoint inhibitor endocrinopathies and the role of advanced practice providers in the management of immune-mediated toxicities

Effects of partly supervised and home-based exercise program in patients undergoing hematopoietic stem cell transplantation: a case-control study

Trekstock RENEW: evaluation of a 12-week exercise referral programme for young adult cancer survivors delivered by a cancer charity

Painful and non-painful chemotherapy-induced peripheral neuropathy and quality of life in colorectal cancer survivors: results from the population-based PROFILES registry

The challenge of timing: a qualitative study on clinician and patient perspectives about implementing exercise-based rehabilitation in an acute cancer treatment setting

Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-related adverse events: pulmonary toxicity

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie